



3EC International a.s., Hraničná 18, 821 05 Bratislava, Slovakia
Notified Body No. 2265

EC CERTIFICATE

No. 2020-MDD/QS-008

issued in compliance with the Council Directive 93/42/EEC as amended by 2007/47/EC, which is implemented by the Slovak Government Decree No. 582/2008 Coll. as amended by 215/2013 Coll., certifies that the medical device of Class III,

Hyaluronan Soft Tissue Filling Gel
Trade Name: Manorui®

manufactured by company


Jining Hangxing E-Commerce Co., Ltd.
No. Commercial Street Complex, Guiyuan Area, Fuqiao District, Rencheng Dist.,
Jining, Shandong, China


is manufactured under conditions fulfilling the quality system requirements of Annex II, excluding (4), of the Directive 93/42/EEC as amended by 2007/47/EC.

The Notified Body No. 2265 has performed an audit of the above device quality system. The full quality assurance system has been assessed, approved and is subject to continuous surveillance according to Annex II, Sections 3.3, and 5, of the Directive 93/42/EEC as amended by 2007/47/EC. The detailed description of the system, requirements and measures applied by the manufacturer are presented in the Audit Report No. 310227 and the Final protocol No. 310227A/2020 that is enclosed to this certificate.

This certificate is issued under the following conditions:

It applies only to the quality system maintained in the manufacture of the above referenced models of medical devices and it does not substitute the design or type-examination procedures, if requested. The certificate remains valid until the manufacturing conditions or the quality system are changed but until November 6th, 2025 at the latest. The certificate validity is conditional upon positive results of regular surveillance audits and fulfillment of relevant legal and other requirements by manufacturer. For the placing on the market of the above referenced models of medical devices covered by this certificate, an EC design-examination certificate according to the Directive 93/42/EEC as amended by 2007/47/EC, Annex II (4) is required.




Dr. Katarina Srdošová
Responsible to act on behalf of NB 2265

In Bratislava, on November 7th, 2020